pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 42 | Non-oncology: 26 Oncology: 16 |
Under Consideration for Negotiation | 12 | Non-oncology: 9 Oncology: 3 |
Completed Negotiations | 793 | With Letter of Intent: 686 Without agreement: 107 |
Negotiations That Were Not Pursued | 108 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Blincyto | Amgen Canada Inc. | Indicated for the pediatric patients with Philadelphia chromosome negative relapsed/refractory B precursor acute lymphoblastic leukemia (ALL) who are in first relapse. | |
Rybrevant | Janssen Inc. | In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) | |
Voydeya | Alexion Pharma GmbH | Paroxysmal nocturnal hemoglobinuria (PNH) |